MMP9-Associated Tumor Stem Cells, CCL1-Silenced Dendritic Cells, and Cytokine-Induced Killer Cells Have a Remarkable Therapeutic Efficacy for Acute Myeloid Leukemia by Activating T Cells

Figure 8

MMP9- and CCL1-silenced DC-CIK cells notably ameliorated T-lymphocyte function in AML model mice. AML model mice were established by injecting HL-60 cells into tail vein and then injected with MMP9- or/and CCL1-silenced DC-CIK cells. (a) Flow cytometry was applied to assess the influences of the modified DC-CIK cells on the T-lymphocyte subsets (CD³⁺CD⁴⁺ and CD³⁺CD⁸⁺) in AML model mice. (b) Flow cytometry was also utilized to confirm the effects of the modified DC-CIK cells on the number of CD4⁺PD-1⁺ and CD8⁺PD-1⁺ cells in AML model mice. (c) The positive rates of CD³⁺CD⁴⁺, CD³⁺CD⁸⁺, CD4⁺PD-1⁺, and CD8⁺PD-1⁺ cells were quantitatively analyzed.

(a)

(b)

(c)